RBC keeps AstraZeneca at ‘outperform’ ahead of AVANZAR lung cancer trial
RBC maintains 'outperform' rating on AstraZeneca (AZN) with a 14,500p target, expecting Q3 revenue of $16.3B, 1.8% above consensus, and core EPS of $2.61. Oncology sales are forecast at $7.1B, led by Tagrisso. Farxiga and Lynparza sales are below consensus. Operating expenses are forecast at $7.9B. The AVANZAR trial is a key catalyst.
How this was made
The 30-second read
Why it matters
The rating upgrade and target price increase suggest a short‑term bullish bias, but execution risk remains around drug sales and patent expiries.
Market read
Analyst upgrade ahead of earnings could prompt buying pressure, especially among European pharma investors.
What to watch
Potential downside from Farxiga patent loss and Lynparza sales decline could temper the upside.
Background
RBC provides a detailed Q3 forecast for AstraZeneca, highlighting oncology revenue, drug-specific expectations, and expense outlook.
Ticker impact
RBC Capital Markets maintained an 'outperform' rating on AstraZeneca and issued a 14,500p target price with updated Q3 revenue and EPS forecasts.
likely modest upside as market prices in the upgraded rating and target
RBC's rating change and target price are new information that can influence investor sentiment ahead of the upcoming earnings release.
Market effects
Positive outlook for the pharmaceutical sector as a major FTSE 100 player receives an upgrade.
May boost European pharma stocks, particularly FTSE 100 constituents.
Limited to investors tracking large-cap pharma; no broad market effect.
Counterpoint
Some investors may view the modest guidance uplift as insufficient given competitive pressures in oncology.
Key entities
- companyAstraZeneca PLC
FTSE 100 pharmaceutical group receiving an 'outperform' rating.
- analystRBC Capital Markets
Issuer of the rating upgrade and target price.
